Effect of Ketamine Treatment on Social Withdrawal in Autism and Autism-Like Conditions.

IF 0.8 4区医学 Q4 CLINICAL NEUROLOGY

Clinical Neuropharmacology Pub Date : 2024-05-01 DOI:10.1097/WNF.0000000000000591

Megan Ralston, Alim Osman, Pavan Suryadevara, Elissa Cleland

{"title":"Effect of Ketamine Treatment on Social Withdrawal in Autism and Autism-Like Conditions.","authors":"Megan Ralston, Alim Osman, Pavan Suryadevara, Elissa Cleland","doi":"10.1097/WNF.0000000000000591","DOIUrl":null,"url":null,"abstract":"Objective: Ketamine and esketamine have been used in the field of psychiatry to alleviate conditions such as major depressive disorder. Our objective was to evaluate the current literature on the use of ketamine for symptoms of social withdrawal in autism spectrum disorder (ASD) and autism-like conditions.Methods: A comprehensive search of PubMed and Web of Science was conducted to identify literature involving the use of ketamine to treat symptoms of autism and social withdrawal. Patients with comorbid disorders were also included.Results: Two original studies were found, showing mixed results on the use of ketamine for ASD. The use of esketamine found no statistically significant results, whereas the use of intravenous ketamine was shown to alleviate symptoms of social withdrawal especially in the short term. Neither study reported a significant amount of serious adverse events. Five case reports were also included, showing decreased depressive symptoms and evidence of increased social condition.Conclusions: Research on the use of ketamine for ASD and ASD-related conditions is limited. Evidence of improved social condition exists, but further studies should be conducted to increase sample power and test various doses and methods of administration.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":"47 3","pages":"97-100"},"PeriodicalIF":0.8000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Neuropharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/WNF.0000000000000591","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Ketamine and esketamine have been used in the field of psychiatry to alleviate conditions such as major depressive disorder. Our objective was to evaluate the current literature on the use of ketamine for symptoms of social withdrawal in autism spectrum disorder (ASD) and autism-like conditions.

Methods: A comprehensive search of PubMed and Web of Science was conducted to identify literature involving the use of ketamine to treat symptoms of autism and social withdrawal. Patients with comorbid disorders were also included.

Results: Two original studies were found, showing mixed results on the use of ketamine for ASD. The use of esketamine found no statistically significant results, whereas the use of intravenous ketamine was shown to alleviate symptoms of social withdrawal especially in the short term. Neither study reported a significant amount of serious adverse events. Five case reports were also included, showing decreased depressive symptoms and evidence of increased social condition.

Conclusions: Research on the use of ketamine for ASD and ASD-related conditions is limited. Evidence of improved social condition exists, but further studies should be conducted to increase sample power and test various doses and methods of administration.

查看原文本刊更多论文

氯胺酮治疗对自闭症和类自闭症患者社交退缩的影响

目的：氯胺酮和艾司氯胺酮已被用于精神病学领域，以缓解重度抑郁症等病症。我们的目的是评估目前使用氯胺酮治疗自闭症谱系障碍（ASD）和类似自闭症的社交退缩症状的文献：我们对 PubMed 和 Web of Science 进行了全面搜索，以确定有关使用氯胺酮治疗自闭症和社交退缩症状的文献。研究还包括合并症患者：结果：发现了两项原始研究，结果显示氯胺酮治疗自闭症的效果不一。使用氯胺酮在统计学上没有显著效果，而静脉注射氯胺酮则可减轻社交退缩症状，尤其是在短期内。两项研究均未报告大量严重不良事件。研究还纳入了五份病例报告，显示抑郁症状有所减轻，有证据表明社交状况有所改善：关于氯胺酮用于治疗自闭症和自闭症相关疾病的研究十分有限。有证据表明氯胺酮可改善社交状况，但应开展进一步的研究，以增加样本力量并测试各种剂量和给药方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Neuropharmacology 医学-临床神经学

CiteScore

1.20

自引率

10.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Clinical Neuropharmacology is a peer-reviewed journal devoted to the pharmacology of the nervous system in its broadest sense. Coverage ranges from such basic aspects as mechanisms of action, structure-activity relationships, and drug metabolism and pharmacokinetics, to practical clinical problems such as drug interactions, drug toxicity, and therapy for specific syndromes and symptoms. The journal publishes original articles and brief reports, invited and submitted reviews, and letters to the editor. A regular feature is the Patient Management Series: in-depth case presentations with clinical questions and answers.